Summary Decreased membrane rigidity is one of the characteristics of malignant cells, resulting in part from the desaturation of stearic acid into oleic acid. In this study we investigated the influence of stearic acid on tumour cell inhibition in vitro and tumour development in vivo. Stearic acid inhibited the colony-forming ability of 4 out of 5 rat and two human tumour continuous cell lines in vitro. In contrast, the colony-forming ability of rat fibroblasts was not inhibited and that of human foetal lung fibroblasts was inhibited at a higher dose than that required to inhibit human tumour cell lines. Using a model of rat mammary carcinoma induced by nitroso-methyl urea (NMU) the subcutaneous injection of stearic acid at weekly intervals prevented tumour development in 5 to 10 rats. Using iodostearic acid twice weekly, 11 of 19 rats were alive and tumour free at week 22 whilst all of 14 animals injected with NMU alone had died of tumour by the 16th week. The ratio of stearic to oleic acids in erythrocyte membranes was significantly reduced in the tumourbearing rats, but was normal in tumour-free animals treated with stearic or iodostearic acid. These preliminary data indicate that stearic acid inhibits tumour development in rats.
The regulation of membrane rigidity is essential for homeostasis (Cooper, 1977) and the metabolic rates of many essential cell enzymes depend on it (Sandemann, 1979) . In general, decreased membrane rigidity leads to increased cell metabolism and also higher division rates, features characteristic of the malignant cell. Corvin et al. (1977) have also shown that alteration of membrane lipid structure may change the cancer cell phenotype. The evidence for decreased membrane rigidity in malignant cells is derived from direct physical measurements and lipid analysis. Using fluorescent probes and magnetic resonance studies, decreased microviscosity (decreased membrane rigidity) was found in plasma membranes, as well as in isolated lipid vesicles from leukaemic cells (Petitou et al., 1978; Mountford et al., 1986) . Fatty acid analysis of lipids extracted from transformed cells, cell lines, leukaemic cells and solid tumour tissue showed a consistent increase in the oleic acid content relative to stearic acid Wood et al., 1985) .
The normal metabolic flow results in conversion of the saturated stearic acid to the monounsaturated oleic acid by the enzyme complex delta 9 desaturase. The ratio of stearic to oleic acid, the so-called saturation index (SI), reflects the activity of this enzyme . A significant decrease in the SI of red blood cell membranes was noted in a range of human and animal malignancies (Habib et al., 1987b) , and it was suggested that this index could be used as a tumour marker. It has also been reported that there is a decrease in the SI of red blood cell membranes in patients suffering from the Acquired Immune Deficiency Syndrome .
We have noted previously that interferon inhibits the desaturation of stearic acid in vitro (Apostolov & Barker, 1981) and that interferon treatment of patients with hairy cell leukaemia leads to improvement in the saturation index in proliferative blood cells (Worman et al., 1987) . It has been suggested that one of the biological activities of interferon could be the inhibitory effect on delta 9 desaturase and subsequent increase in stearic acid and membrane rigidity (Apostolov & Barker, 1981) . These findings prompted the study of the possible use of exogenous stearic acid to prevent or reverse the desaturation of cell membrane stearic acid and thereby inhibit cell division both in vitro and in vivo. In vivo experiment with stearic acid To study the influence of stearic acid in vivo, an established animal model was used. N-nitrosomethyl urea (NMU) rapidly induces mammary carcinoma in rats (Chan et al., 1977; Gullino et al., 1975) and does not require metabolic activation (Preussmann & Stewart, 1984) .
Materials and methods

Clonogenic
Thirty female Sprague-Dawley rats weighing -200g each were divided into 2 groups. The first (n=20) received NMU only, the second (n = 10) received NMU plus stearic acid.
NMU in 3% acetic acid (Sigma Chemicals, UK) was dissolved in distilled water (20mgml-1) and was given in three i.v. injections of 5mg 100 g1 body wt, at weeks 1, 4 and 8. Stearic acid (Sigma Chemicals, UK) (0.5 mg) dissolved in liquid paraffin (0.5ml) was injected at weekly intervals s.c. in the flank, starting from the second week. The parenteral route of administration was preferred for our study in order to avoid first call metabolism by the liver of orally-administered lipids.
The onset of tumours was monitored by daily inspection and by palpation of the mammary regions twice weekly. At week 22 of the experiment, all surviving animals were sacrificed, autopsies were performed and the tumours were dissected and examined histologically.
In vivo experiment with iodostearic acid A similar investigation was performed using iodostearic acid in place of stearic acid, since it is more readily soluble in lipid solvent than the parent compound. Oleic acid was commercially purchased (Sigma Chemicals, UK) and iodinated by passing dry hydrogen iodide gas in nitrogen through oleic acid at 4°C. Excess iodine was removed at the end of the reaction by the addition of an excess of sodium thiosulphate. The product of these reactions was a mixture of 9 iodo-octadecanoic, 10 iodo-octadecanoic and 9, 10 diiodo-octadecanoic acids. These can be collectively referred to as iodinated stearic acid.
Fifty-nine female Sprague-Dawley rats weighing -200 g each were divided into 3 groups. The first group (n = 15) was injected with NMU alone. The second group (n=21) received NMU and alpha2 interferon (Schering). The third group (n=23) received NMU plus iodostearic acid dissolved in liquid paraffin. NMU in 3% acetic acid was dissolved in distilled water (20mgml-1) and given in two i.v. injections of 7mg 100 g 1 body wt, the second injection following three weeks after the first. Alpha2 interferon was administered i.m. in a dose of 80,000 IU kg-1 twice each week throughout the experiment. lodostearic acid was given s.c. in a dose of 0.5mg twice a week throughout the experiment starting from the 5th week.
Tumour onset was monitored as in the previous experiment. Throughout the experiment only rats that had ulcerated tumours or developed cachexia and marked weakness were sacrificed. In vivo experiment with stearic acid Nineteen of the 20 rats in the NMU alone group developed mammary tumours by week 16 of the experiment, with a mean latent period of 72 days. These 19 rats had a total of 51 tumours, giving a mean of 2.68 tumours/rat, range 1-5. The range of tumour weight/rat was 5 g to 47.8 g with a mean of 23.6/rat, excluding the tumour free rats.
Five of the 10 rats in the NMU plus stearic acid group developed mammary tumours by week 16 of the experiment, with a mean latent period of 74 days. These 5 rats had 7 tumours between them, with a mean of 1.4 tumours/rat (compared to NMU alone group P<0.001). The range of tumour weight/rat was 4.2g to 21.2g, with an average of 16.4g/rat (P<0.01 compared to NMU alone group). By week 22, 19 of the 20 rats in the NMU group were dead with tumours, in contrast with only 2 of 10 rats in the NMU+stearic acid group. Of the remaining 8 that were killed, only 3 had tumours and 5 were tumour-free.
All tumours were examined histologically and were adenocarcinomas.
In vivo experiment with iodostearic acid Figure I shows the results of this experiment. In the NMU alone group one rat died following the first injection of carcinogen. Of the remaining 14 animals, all developed tumours with a mean latent period of 74 days. These rats had 54 tumours between them, giving a mean of 3.8 tumours/rat (range 1-6). Tumour weight/rat ranged from 5g to 53.5 g with a mean of 23.6 g tumour/rat.
Two rats in the NMU plus interferon group died following carcinogen injection. All the remaining 19 rats developed tumour, with a mean latent period of 77 days. The rats with tumour had 63 tumours between them (range Time (weeks) Figure I Percentage of tumour free animals in relation to treatment: NMU; 0 NMU + interferon; NMU + iodostearic acid. 1-6) with a mean of 3.3 tumours/rat. Tumour weight/rat ranged from 3.8 g to 34.5 g with a mean of 19 g/rat. None of these results were appreciably different from controls. In the NMU group treated with iodostearic acid, 4 rats died following carcinogen injection. Of the remaining 19 rats, 8 developed tumour with a mean latent period of 76 days. The 8 rats had a mean of 2.7 tumours/rat, with a range of 1-5. Four had extensive tumours (>4cm diam.), and 2 had tumours between 2-4 cm. The remaining two rats had massive tumours ( > 4 cm) which regressed subsequently to less than 2 cm on continued treatment with iodostearic acid. At week 22, eleven of the 19 rats treated with NMU plus iodostearic acid were still alive and without tumour.
All the tumours examined histologically were adenocarcinomas.
Gas-liquid chromatography analysis of rat erythrocytes Figure 2 shows the mean and standard deviation of the SI in each group of rats. The mean SI of the normal saline group was 2.0+0.3. In the NMU group, the erythrocyte SI fell consistently in all rats (P<0.001) to a mean of 1.09+0.28. Similarly, the SI was significantly reduced in rats receiving interferon (mean = 1.1 + 0.16). By contrast, those rats receiving iodostearic acid that were tumour-free had an SI of 2.12+0.42. Moreover, the tumour-bearing animals receiving iodostearic acid had an SI (mean 1.79+0.33) that was higher than the group with NMU alone (P<0.002), but lower than that of tumour-free animals.
Discussion
This study has shown that stearic acid significantly inhibits the colony-forming ability of some tumour cell lines, in a dose-related manner. Although human cancer cells appear more sensitive to stearic acid than rat cancer cells, the methodology and culture conditions differed. Other workers have shown a similar effect in vitro with a non selective incorporation of fatty acids into cell phospholipids (Doi et al., 1978; Wicha et al., 1979) . In those studies the addition of oleic acid had either no effect or stimulated cell division. An important feature of our work has been the demonstration that parenteral administration of stearic acid in vivo can prevent the development of tumours in an experimental animal model. We have also provided indirect evidence that inhibition of mammary carcinogenesis is linked to the maintenance of a normal saturation index within the cell membranes. By preserving the ratio of saturated to unsaturated fatty acid, the membrane rigidity remains normal and cell division is inhibited. Those animals that developed tumours despite treatment with stearic acid had significantly fewer and smaller tumours than the animals given carcinogen alone. Their saturation index in erythrocyte membranes was lower than that of tumour-free animals, but was still significantly higher than that of rats given carcinogen without stearic acid. These observations on the erythrocyte saturation index were the same whether the rats were injected with stearic acid or iodostearic acid (data not included).
We have previously shown that a decrease in the saturation index of red blood cell membranes is a characteristic finding in patients with a variety of cancers. That this is a reversible change is shown by the return to normal of the saturation index after surgical excision of the tumour, and a subsequent fall with tumour recurrence. Erythrocytes were chosen because they are endstage non-dividing cells with only one plasma membrane. The extraction procedure used measured the total fatty lipids of the cell membrane rather than the free fatty acids. We have also shown that the drop in saturation index of erythrocytes observed in human cancer can also be seen in rats developing colonic carcinomas following exposure to dimethylhydrazine (Habib et al., 1987b ), but does not occur in rats with nutritional cachexia (unpublished observation). Similar changes in cell membrane lipid composition also occur in human leucocytes and platelets in cancer patients , suggesting the presence of a desaturation producing factor (DPF) released by the tumour (Habib et al., 1987a) . We therefore postulate that an alteration in the fatty acid composition of cell membranes may play a role in the carcinogenic process (Habib et al., 1987b) .
The ability to prevent the alteration in the ratio of fatty acids, as suggested by this study, may either inhibit or merely delay primary oncogenesis. It remains to be shown whether stearic or iodostearic acid have a direct effect on the erythrocyte cell membranes or whether the response is secondary to changes in the bone marrow. It is interesting to note that in two rats tumours actually regressed with continued stearic acid therapy. If confirmed, this finding raises the possibility that in addition to inhibiting cell division, altering the fatty acid structure of the membrane may have a direct anti-tumour effect. Future work will investigate the role of stearic acid and its derivatives in the treatment of neoplasia by studying the effect on established tumours growing as transplants.
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